BCAL Diagnostics Limited (AU:BDX) has released an update.
BCAL Diagnostics Limited reports an 8.6% increase in revenue and a 26% increase in net loss for the financial year ending June 30, 2024, compared to the previous year. The company is gearing up for the commercial launch of its proprietary BREASTEST blood test, with significant investments in clinical partnerships and technology for sample analysis. Additionally, BCAL is expanding its IP portfolio and preparing its laboratory in North Carolina for a September opening to boost research and development efforts in the US.
For further insights into AU:BDX stock, check out TipRanks’ Stock Analysis page.
